SEC Filing Summary: Bioptix, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Bioptix, Inc. on April 10, 2017. The report addresses a corporate governance issue regarding compliance with Nasdaq listing standards. Note: The request metadata referenced "Riot Platforms, Inc.", but the provided filing text explicitly identifies the registrant as Bioptix, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance matter and contains no financial performance data.
Material Changes
- Executive Appointment: Mr. Michael M. Beeghley was appointed Chief Executive Officer effective April 6, 2017.
- Independence Status: Due to the CEO appointment, Mr. Beeghley is no longer considered an independent director.
- Audit Committee Composition: The audit committee now consists of only two independent members, falling below the required minimum of three.
- Regulatory Notice: The Company received a notice of deficiency from Nasdaq on April 10, 2017, citing non-compliance with Listing Rule 5605.
Outlook, Risks, and Management Commentary
Cure Period: Nasdaq has granted the Company a cure period to regain compliance. The deadline is the earlier of the next annual shareholders' meeting or April 6, 2018. If the next annual meeting occurs before October 3, 2017, compliance must be evidenced by October 3, 2017.
Management Plan: The Company expects to regain compliance by appointing an additional independent director to the Board of Directors and the audit committee prior to the end of the cure period.
Risks: Failure to regain compliance within the specified timeframe could result in the delisting of the Company's securities from The Nasdaq Stock Market.
Key Facts for Investor Verification
- Verify the current composition of the Bioptix, Inc. Board of Directors and Audit Committee.
- Confirm the date of the next annual shareholders' meeting to determine the exact compliance deadline.
- Monitor for the appointment of a new independent director to satisfy Nasdaq Listing Rule 5605.
- Check for any subsequent filings regarding the status of the delisting risk.